SC-VC-PAB-MMAE is a cleavable drug-linker conjugate incorporating the tubulin inhibitor monomethyl auristatin E (MMAE). It is a key component for constructing antibody-drug conjugates (ADCs) for cancer research, enabling targeted delivery and release of the cytotoxic payload in both in vitro and in vivo experimental models.